文献速递血栓与止血造血干细胞移植与细胞治疗

依库珠单抗克服HLA同种免疫患者血小板输注无效的初步试验

A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
PubMed 文献 · Br J Haematol · 2020-02-21

该初步试验纳入10例HLA同种免疫伴严重血小板减少的患者,单次给予依库珠单抗(C5单抗)输注。4例(40%)患者通过输注后10–60分钟和18–24小时的校正血小板计数增量(CCI)评估克服了血小板输注无效,且 responders 后续血小板输注需求减少、输注后14天内血小板增量更高。

要点

  • 单次依库珠单抗可使40%的HLA同种免疫血小板输注无效患者达到CCI应答标准
  • 4例应答者中3例在输注HLA不相合血小板时仍满足CCI应答标准
  • 应答者后续血小板输注需求减少且14天内血小板增量更高

核心结论

  • 依库珠单抗可能克服广泛HLA同种免疫患者的血小板输注无效,补体抑制治疗血小板输注无效的 principle 得到初步验证。

研究设计与样本

  • 初步试验纳入10例HLA同种免疫伴严重血小板减少的合格患者,单次给予依库珠单抗输注。
  • 通过输注后10–60分钟和18–24小时的校正血小板计数增量(CCI)评估血小板输注无效是否被克服。

主要发现

  • 4例(40%)患者克服了血小板输注无效。
  • 应答者后续血小板输注需求减少,且依库珠单抗给药后14天内输注后血小板增量更高。
  • 4例应答者中3例在输注HLA不相合血小板时仍满足CCI应答标准。

关键数值与推荐

  • 以输注后10–60分钟和18–24小时的校正血小板计数增量(CCI)评估应答。
  • 10例中4例(40%)达到克服血小板输注无效的应答。

临床怎么用

  • 对于HLA同种免疫导致血小板输注无效且严重血小板减少的患者,可考虑单次依库珠单抗输注作为克服输注无效的尝试。
  • 疗效评估可采用输注后10–60分钟和18–24小时的CCI,并关注后续血小板输注需求和14天内血小板增量。

局限性

  • 为初步试验,样本量仅10例,需大型多中心试验评估总体疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heavily transfused patients frequently develop human leukocyte antigen (HLA) allo-immunization resulting in platelet transfusion refractoriness and a high risk for life-threatening thrombocytopenia. Data suggest complement activation leading to the destruction of platelets bound by HLA allo-antibodies may play a pathophysiologic role in platelet refractoriness. Here we conducted a pilot trial to investigate the use of eculizumab, a monoclonal antibody that binds and inhibits C5 complement, to treat platelet transfusion refractoriness in allo-immunized patients with severe thrombocytopenia. A single eculizumab infusion was administered to 10 eligible patients, with four (40%) patients overcoming platelet refractories assessed measuring the corrected platelet count increment (CCI) 10-60 min and 18-24 h post transfusion. Responding patients had a reduction in the requirement for subsequent platelet transfusions and had higher post-transfusion platelet increments for 14 days following eculizumab administration. Remarkably, three of the four responders met CCI criteria for response despite receiving HLA-incompatible platelets. Our results suggest that eculizumab has the ability to overcome platelet transfusion refractoriness in patients with broad HLA allo-immunization. This study establishes proof of principle that complement inhibition can treat platelet transfusion refractoriness, laying the foundation for a large multicentre trial to assess the overall efficacy of this approach (ClinicalTrials.gov, identifier: NCT02298933).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Vo P, Purev E, West KA, et al. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Br J Haematol. 2020. PMID: 32086819. doi:10.1111/bjh.16385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。